Bio-Rad Laboratories (NYSE:BIO) EVP James Barry Sells 1,400 Shares of Stock

Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP James Barry sold 1,400 shares of the business’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $385.63, for a total value of $539,882.00. Following the completion of the sale, the executive vice president owned 625 shares in the company, valued at $241,018.75. This represents a 69.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Bio-Rad Laboratories Price Performance

BIO opened at $370.41 on Friday. The stock’s 50-day moving average price is $373.46 and its 200 day moving average price is $317.11. Bio-Rad Laboratories, Inc. has a 12-month low of $236.73 and a 12-month high of $396.23. The company has a current ratio of 3.18, a quick ratio of 2.37 and a debt-to-equity ratio of 0.11. The firm has a market cap of $9.90 billion, a price-to-earnings ratio of 9.76 and a beta of 1.06.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Wednesday, November 4th. The medical research company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.23 by $0.42. The company had revenue of $656.40 million during the quarter, compared to the consensus estimate of $649.94 million. Bio-Rad Laboratories had a return on equity of 3.58% and a net margin of 39.45%. Bio-Rad Laboratories’s revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the company posted $2.26 EPS. As a group, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 9.71 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its holdings in shares of Bio-Rad Laboratories by 57.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 233,227 shares of the medical research company’s stock valued at $68,478,000 after purchasing an additional 85,393 shares in the last quarter. Wellington Management Group LLP purchased a new position in Bio-Rad Laboratories in the second quarter valued at $17,690,000. Hound Partners LLC increased its holdings in Bio-Rad Laboratories by 125.9% in the first quarter. Hound Partners LLC now owns 97,724 shares of the medical research company’s stock valued at $27,241,000 after buying an additional 54,456 shares during the last quarter. Amundi increased its holdings in Bio-Rad Laboratories by 1,763.4% in the first quarter. Amundi now owns 38,778 shares of the medical research company’s stock valued at $10,809,000 after buying an additional 36,697 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in Bio-Rad Laboratories in the first quarter valued at $5,098,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Bio-Rad Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday. Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Citigroup raised their price target on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada boosted their price target on shares of Bio-Rad Laboratories from $390.00 to $440.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Finally, Wells Fargo & Company boosted their price target on shares of Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $366.67.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.